Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil OTC Recalls Slice $900M From J&J's 2010 Sales

This article was originally published in The Tan Sheet

Executive Summary

Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.
Advertisement

Related Content

J&J Plans To Upgrade Recalled OTCs for Relaunch
Trends That Affected OTC Sales In 2010
Homeopathy Gains From J&J Recalls As Consumers, Retailers Seek Alternatives
Weldon Takes Compensation Hit Due To OTC Recalls, But J&J Touts His Steering
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
In Brief
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
J&J Washes Hands Of Purell As GOJO Eyes Consumer Segment Growth
J&J Washes Hands Of Purell As GOJO Eyes Consumer Segment Growth
Startup Blacksmith Debuts With Luden's, PediaCare Acquisition From McNeil
Advertisement
UsernamePublicRestriction

Register

PS104829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel